SYS-CON MEDIA Authors: Gilad Parann-Nissany, RealWire News Distribution

News Feed Item

FDA Reviews, Trial Initiation, New Innovations, and Multi-year Commercial Agreement - Research Report on Sanofi, Medivation, Align Technology, WuXi PharmaTech, and Insulet

NEW YORK, December 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Sanofi SA (NYSE: SNY), Medivation, Inc. (NASDAQ: MDVN), Align Technology, Inc. (NASDAQ: ALGN), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), and Insulet Corporation (NASDAQ: PODD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Sanofi SA Research Report

On December 11, 2013, Sanofi SA (Sanofi), along with its subsidiary Genzyme, announced that the FDA has granted a six-month Priority Review designation to Genzyme's NDA for Cerdelga (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1. The Company reported that Genzyme is developing eliglustat and the clinical development for this drug is said to be the largest clinical program ever conducted in Gaucher disease, with approximately 400 patients treated in 29 countries. According to the Company, FDA's Priority Review designation signifies that its goal is to take action on the NDA within six months, compared to 10 months under standard review. The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/29ea_SNY

Medivation, Inc. Research Report

On December 4, 2013, Medivation, Inc. (Medivation) and Astellas Pharma US, Inc. (Astellas) jointly announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of enzalutamide in combination with exemestane in women with advanced breast cancer that is estrogen receptor positive (ER+) or progesterone receptor positive (PgR+) and human epidermal growth factor receptor 2 (HER2) normal. "Exemestane is a commonly used aromatase inhibitor in patients whose tumors express either the estrogen or progesterone receptor. It is our hope that inhibiting androgen receptor signaling with enzalutamide in combination with exemestane will provide benefit beyond the inhibition of estrogen and progesterone signaling in patients with advanced breast cancer," said Lynn Seely, M.D., Chief Medical Officer of Medivation. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4277_MDVN

Align Technology, Inc. Research Report

On December 3, 2013, Align Technology, Inc. (Align Technology) announced the upcoming release of Invisalign G5 innovations, specifically designed for the treatment of deep bite malocclusions. "Invisalign G5 is our first set of innovations designed to enhance treatment predictability for a specific type of malocclusion," said John P. Graham, Vice President of Marketing and Chief Marketing Officer of Align Technology. "Deep bite is a very prevalent, functional problem that is important to correct, with an estimated 45 percent of adult and teen patients presenting with this orthodontic problem. We're pleased to introduce this set of innovative features that addresses such a big part of our customers' practices and that will help drive increased utilization of Invisalign over time." The Company expects Invisalign G5 innovations for deep bite to be available in Q1 2014. The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/69b3_ALGN

WuXi PharmaTech (Cayman) Inc. Research Report

On December 10, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced the winners of its seventh annual WuXi PharmaTech Life Science and Chemistry Awards at a ceremony held on December 7, 2013, in Beijing. The Company has presented the awards to 15 highly accomplished young scholars. The Company reported that these awards originated in 2007 and aim to foster early innovation and to encourage pursuit of excellence in life science research. "We are excited to recognize some of the brightest minds in China through our Life Science and Chemistry Awards," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Their excellent research has the potential to substantially help our industry to better understand diseases and to find cures that benefit patients around the world." The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df7b_WX

Insulet Corporation Research Report

On December 10, 2013, Insulet Corporation (Insulet) announced a five-year commercial agreement with Amgen Inc. (Amgen), under which Insulet will supply Amgen with a delivery device, built using its tubeless insulin pump technology, which is specifically designed around the unique delivery needs of biotechnology medicines. "Insulet's current device, the OmniPod®, is a unique drug delivery platform that provides the ability to vary rate at which medication is infused. With over 25 million OmniPods produced, our innovative product is the undisputed global leader in patch pump technology and provides a patient-friendly and cost effective drug delivery alternative," said Duane DeSisto, President and CEO of Insulet. The Full Research Report on Insulet Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/75e4_PODD

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.